[Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy]. [Article in Chinese]
Author(s): Chen YB(1), Hao YP, Hao XS, Liang D.
Affiliation(s): Author information:
(1)Department of Pediatric Neurology, First Hospital of Jilin University, Changchun
130021, China.
Publication date & source: 2013, Zhongguo Dang Dai Er Ke Za Zhi. , 15(5):340-2
OBJECTIVE: To investigate the clinical efficacy and safety of oxcarbazepine (OXC)
suspension in children with focal epilepsy.
METHODS: A total of 118 children aged 2-14 years, who were newly diagnosed with
focal epilepsy between October 2009 and December 2011, were randomly divided into
experimental group (n=60) and control group (n=58). The experimental group was
treated with an orally suspension of OXC and the control group was orally
administered with carbamazepine (CBZ) tablets. The two treatment regimens were
compared in terms of clinical efficacy and safety.
RESULTS: After 13 and 26 weeks of treatment, the experimental group had response
rates of 75% and 72% respectively and seizure-free rates of 53% and 50%, and the
control group had response rates of 71% and 66% and seizure-free rates of 50% and
43% respectively. There were no significant differences in the clinical efficacy
between the two groups (P>0.05). After 26 weeks of treatment, the adverse event
rates of the experimental and control groups were 18% and 40% respectively, with
a significant difference between the two groups (P<0.05).
CONCLUSIONS: OXC suspension has a comparable clinical efficacy to that of CBZ
tablets in children aged 2-14 years who are newly diagnosed with focal epilepsy,
but OXC suspension causes fewer adverse events and has higher safety.
|